BR112015021471A2 - compostos acilaminocicloalquila adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3 - Google Patents
compostos acilaminocicloalquila adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3Info
- Publication number
- BR112015021471A2 BR112015021471A2 BR112015021471A BR112015021471A BR112015021471A2 BR 112015021471 A2 BR112015021471 A2 BR 112015021471A2 BR 112015021471 A BR112015021471 A BR 112015021471A BR 112015021471 A BR112015021471 A BR 112015021471A BR 112015021471 A2 BR112015021471 A2 BR 112015021471A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- fluorinated
- group
- alkoxy
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101150097070 Drd3 gene Proteins 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000005475 oxolanyl group Chemical group 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 | |
| US201361918524P | 2013-12-19 | 2013-12-19 | |
| PCT/EP2014/055062 WO2014140246A1 (en) | 2013-03-15 | 2014-03-14 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015021471A2 true BR112015021471A2 (pt) | 2017-07-18 |
Family
ID=50280387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015021471A BR112015021471A2 (pt) | 2013-03-15 | 2014-03-14 | compostos acilaminocicloalquila adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9388148B2 (https=) |
| EP (1) | EP2970146B1 (https=) |
| JP (1) | JP2016514117A (https=) |
| CN (1) | CN105339357A (https=) |
| AU (1) | AU2014230215A1 (https=) |
| BR (1) | BR112015021471A2 (https=) |
| CA (1) | CA2902656A1 (https=) |
| MX (1) | MX2015012184A (https=) |
| TW (1) | TW201514154A (https=) |
| UY (1) | UY35420A (https=) |
| WO (1) | WO2014140246A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| AR095264A1 (es) * | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| EP3744721B1 (en) | 2018-01-26 | 2025-07-02 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| AU2020376090A1 (en) * | 2019-10-29 | 2022-04-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Modifier of four-membered ring derivative, preparation method and application thereof |
| TWI873212B (zh) * | 2019-10-29 | 2025-02-21 | 大陸商上海翰森生物醫藥科技有限公司 | 四員環類衍生物調節劑、其製備方法和應用 |
| CN113754580B (zh) | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| CA3216904A1 (en) * | 2021-04-28 | 2022-11-03 | Jinyao CHEN | Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| ES2340941T3 (es) | 2004-08-09 | 2010-06-11 | ABBOTT GMBH & CO. KG | Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina. |
| DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| WO2009003868A2 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| JP5367824B2 (ja) * | 2008-09-22 | 2013-12-11 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬 |
| AU2009296047A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors |
| US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-13 UY UY0001035420A patent/UY35420A/es not_active Application Discontinuation
- 2014-03-14 WO PCT/EP2014/055062 patent/WO2014140246A1/en not_active Ceased
- 2014-03-14 TW TW103109325A patent/TW201514154A/zh unknown
- 2014-03-14 JP JP2015562180A patent/JP2016514117A/ja active Pending
- 2014-03-14 MX MX2015012184A patent/MX2015012184A/es unknown
- 2014-03-14 BR BR112015021471A patent/BR112015021471A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/213,169 patent/US9388148B2/en active Active
- 2014-03-14 CA CA2902656A patent/CA2902656A1/en not_active Abandoned
- 2014-03-14 CN CN201480026453.XA patent/CN105339357A/zh active Pending
- 2014-03-14 AU AU2014230215A patent/AU2014230215A1/en not_active Abandoned
- 2014-03-14 EP EP14710261.0A patent/EP2970146B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016514117A (ja) | 2016-05-19 |
| EP2970146A1 (en) | 2016-01-20 |
| AU2014230215A1 (en) | 2015-09-03 |
| TW201514154A (zh) | 2015-04-16 |
| WO2014140246A1 (en) | 2014-09-18 |
| CA2902656A1 (en) | 2014-09-18 |
| US20140303176A1 (en) | 2014-10-09 |
| EP2970146B1 (en) | 2017-11-01 |
| CN105339357A (zh) | 2016-02-17 |
| UY35420A (es) | 2014-10-31 |
| MX2015012184A (es) | 2016-05-16 |
| US9388148B2 (en) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015021471A2 (pt) | compostos acilaminocicloalquila adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3 | |
| BR112015008992A2 (pt) | compostos de acilaminocicloalquila adequados para tratamento de distúrbios que respondem à modulação de receptor d3 de dopamina | |
| MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
| UY33969A (es) | Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3 | |
| BR112014004971A8 (pt) | heterociclilaminas como inibidores de pi3k | |
| MX2014013858A (es) | Metodo para tratar un cancer positivo de gd2. | |
| MX341446B (es) | Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes). | |
| PH12014502413A1 (en) | Cyclic bridgehead ether dgat1 inhibitors | |
| BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
| CO7160030A2 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| CO6251282A2 (es) | Oxazolidinonas sustituidas y su uso | |
| PH12016501507A1 (en) | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | |
| BR112016012123A8 (pt) | composto de triazolo-piridina | |
| CO6410257A2 (es) | Herbicidas novedosos | |
| AR075158A1 (es) | Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos. | |
| BR112013024223A2 (pt) | composto de poliéter, agente de cura usando o composto de poliéter, e método de produção do composto de poliéter | |
| BR112020022088A8 (pt) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| BR112013010316A2 (pt) | curtimento com não metal | |
| BRPI0713743B8 (pt) | composto, e, composição farmacêutica | |
| JO3264B1 (ar) | مركبات ازيتيدينيل أوكسي فينيل بيروليدين | |
| BR112012014196A2 (pt) | agente para prevenir ou melhorar a pigmentação | |
| BR112012017157A2 (pt) | agente profilático ou de melhora da pigmentação. | |
| BR112013003613A2 (pt) | método de aumentar a estabilidade química e/ou térmica do pha em biomassa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |